
    
      This is a single arm, open-label, single-center study. This study is indicated for relapsed
      or refractory central nervous system CD19+ B-cell hematological malignancies, including acute
      lymphoblastic leukemia and B-cell non-Hodgkin's lymphoma. The selections of dose levels and
      the numberof subjects are based on clinical trialsof similar foreign products. Two groups of
      patients will be enrolled, 36 in eachgroup. Primary objective is to explore the safety, main
      consideration is dose-related safety.
    
  